Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism

scientific article published on 01 May 2015

Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ART.39039
P698PubMed publication ID25605003

P50authorPier Luigi MeroniQ38544871
Nicoletta RondaQ40083991
Francesca ZimettiQ40351192
Maria Orietta BorghiQ47504194
Ennio Giulio FavalliQ51741925
Elda FavariQ88828463
Franco BerniniQ92546543
Rita GattiQ114294879
P2093author name stringIvana Hollan
Knut Mikkelsen
Maria Pia Adorni
Daniela Greco
Gunnbjørg Hjeltnes
P433issue5
P921main subjectlipoproteinQ28350
macrophageQ184204
adalimumabQ348260
methotrexateQ422232
P304page(s)1155-1164
P577publication date2015-05-01
P1433published inArthritis & RheumatologyQ4797636
P1476titleNewly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism
P478volume67

Reverse relations

cites work (P2860)
Q88461341Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis
Q41143656Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis
Q47168123Blood-brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice
Q38737288Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk
Q88917533Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis
Q40959053Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis
Q47154672Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9.
Q38680931High-density lipoprotein function in rheumatoid arthritis
Q90250474IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD
Q90389973Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology
Q52312175Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.
Q49721726Lipids in RA: Is Less Not Necessarily More?
Q42682318Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis
Q36162860Patients with Rheumatoid Arthritis Show Altered Lipoprotein Profiles with Dysfunctional High-Density Lipoproteins that Can Exacerbate Inflammatory and Atherogenic Process
Q40083837Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction.
Q50055620Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma
Q49603124Potential of anti-inflammatory agents for treatment of atherosclerosis
Q59135667Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate
Q38794852Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?
Q60959818Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?
Q50109832The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
Q36000249The challenging interplay between rheumatoid arthritis, ageing and comorbidities
Q48227295Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis

Search more.